Skip to main content
. Author manuscript; available in PMC: 2022 Mar 1.
Published in final edited form as: Brain Behav Immun. 2021 Jan 7;93:80–95. doi: 10.1016/j.bbi.2020.12.016

Figure 3. Systemic administration of the TLR2/TLR4 antagonist (+)-Naltrexone [(+)-NTX] beginning 36 days after intradermal myelin oligodendrocyte glycoprotein (MOG), reverses EAE-related pain in male Dark Agouti rats; no effect on motor scores.

Figure 3.

Male Dark Agouti rats were baselined (BL) for motor scores and for low-threshold mechanical withdrawal thresholds via the von Frey test, followed by intra-dermal low-dose (4-µg) myelin oligodendrocyte glycoprotein (MOG). Allodynia and motor scores were assessed thereafter across the timecourse shown. (+)-NTX (6 mg/kg subcutaneously [SC] 3x/day) vs. saline was initiated on Day 36 post-MOG, continuing through day 50 (see gray rectangle indicating span of drug delivery). Panels A and B: (+)-NTX reversed allodynia, relative to saline control. Main effect of drug: left paw: F(1,10) =1452, p<0.0001; right paw: F(1,10) =3956, p<0.0001. Panel C: (+)-NTX did not reliably increase motor scores. N=6/group.